These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 30875076

  • 1. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
    Hermosilla J, Sánchez-Martín R, Pérez-Robles R, Salmerón-García A, Casares S, Cabeza J, Cuadros-Rodríguez L, Navas N.
    BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
    [Abstract] [Full Text] [Related]

  • 2. Biosimilarity under stress: A forced degradation study of Remicade® and Remsima™.
    Pisupati K, Benet A, Tian Y, Okbazghi S, Kang J, Ford M, Saveliev S, Sen KI, Carlson E, Tolbert TJ, Ruotolo BT, Schwendeman SP, Schwendeman A.
    MAbs; 2017 Oct; 9(7):1197-1209. PubMed ID: 28787231
    [Abstract] [Full Text] [Related]

  • 3. CT-P13 (Inflectra™, Remsima™) monitoring in patients with inflammatory bowel disease.
    Schulze K, Koppka N, Lutter F, Brandhorst G, Schreiber S, Helwig U.
    Biologicals; 2016 Sep; 44(5):463-6. PubMed ID: 27435444
    [Abstract] [Full Text] [Related]

  • 4. A review of CT-P13: an infliximab biosimilar.
    McKeage K.
    BioDrugs; 2014 Jun; 28(3):313-21. PubMed ID: 24723086
    [Abstract] [Full Text] [Related]

  • 5. Stability of infliximab solutions in different temperature and dilution conditions.
    Tokhadze N, Chennell P, Le Basle Y, Sautou V.
    J Pharm Biomed Anal; 2018 Feb 20; 150():386-395. PubMed ID: 29287266
    [Abstract] [Full Text] [Related]

  • 6. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J, Kudrin A.
    Immunotherapy; 2015 Feb 20; 7(2):73-87. PubMed ID: 25713985
    [Abstract] [Full Text] [Related]

  • 7. Stability study over time of clinical solutions of ziv-aflibercept prepared in infusion bags using a proper combination of physicochemical and functional strategies.
    Hermosilla J, Pérez-Robles R, Salmerón-García A, Casares S, Cabeza J, Navas N.
    J Pharm Biomed Anal; 2021 Sep 05; 203():114209. PubMed ID: 34153938
    [Abstract] [Full Text] [Related]

  • 8. Physicochemical characterization of Remsima.
    Jung SK, Lee KH, Jeon JW, Lee JW, Kwon BO, Kim YJ, Bae JS, Kim DI, Lee SY, Chang SJ.
    MAbs; 2014 Sep 05; 6(5):1163-77. PubMed ID: 25517302
    [Abstract] [Full Text] [Related]

  • 9. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.
    Ben-Horin S, Yavzori M, Benhar I, Fudim E, Picard O, Ungar B, Lee S, Kim S, Eliakim R, Chowers Y.
    Gut; 2016 Jul 05; 65(7):1132-8. PubMed ID: 25897019
    [Abstract] [Full Text] [Related]

  • 10. Part 1: Physicochemical characterization of bevacizumab in undiluted 25 mg/mL drug product solutions: Comparison of originator with a biosimilar candidate.
    Arvinte T, Palais C, Poirier E, Cudd A, Rajendran S, Brokx S, Dowd J.
    J Pharm Biomed Anal; 2019 Oct 25; 175():112742. PubMed ID: 31344647
    [Abstract] [Full Text] [Related]

  • 11. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, Sariego IG, Abud-Mendoza C, Escalante WJ, Kang SW, Andersone D, Blanco F, Hong SS, Lee SH, Braun J.
    Arthritis Res Ther; 2016 Jan 20; 18():25. PubMed ID: 26795209
    [Abstract] [Full Text] [Related]

  • 12. Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion.
    Vimpolsek M, Gottar-Guillier M, Rossy E.
    Drugs R D; 2019 Jun 20; 19(2):127-140. PubMed ID: 30810925
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. One-month stability study of a biosimilar of infliximab (Remsima®) after dilution and storage at 4°C and 25°C.
    Vieillard V, Astier A, Sauzay C, Paul M.
    Ann Pharm Fr; 2017 Jan 20; 75(1):17-29. PubMed ID: 27659414
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
    Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, Baranauskaite A, Wiland P, Abud-Mendoza C, Oparanov B, Smiyan S, Kim H, Lee SJ, Kim S, Park W.
    Ann Rheum Dis; 2017 Feb 20; 76(2):355-363. PubMed ID: 27130908
    [Abstract] [Full Text] [Related]

  • 20. Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease.
    Smits LJT, Grelack A, Derikx LAAP, de Jong DJ, van Esch AAJ, Boshuizen RS, Drenth JPH, Hoentjen F.
    Dig Dis Sci; 2017 Nov 20; 62(11):3117-3122. PubMed ID: 28667429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.